Lupin India GLP-1 Drug Deal – Gan & Lee Partnership
- On Monday, December 29, 2023, Lupin Limited announced a strategic partnership with Gan & Lee Pharmaceutical Co., Ltd.
- This collaboration underscores Lupin's commitment to addressing the escalating prevalence of metabolic diseases in india.
- A key differentiator of Bofanglutide is its convenient fortnightly (every two weeks) dosing schedule.
“`html
Lupin Partners with gan & Lee to Bring Bofanglutide, a Novel Diabetes Drug, to India
Table of Contents
Published December 29, 2023, at 4:25 PM PST
Lupin and Gan & Lee Announce strategic Partnership
On Monday, December 29, 2023, Lupin Limited announced a strategic partnership with Gan & Lee Pharmaceutical Co., Ltd. to bring Bofanglutide,a novel treatment for type 2 diabetes,to the Indian market.The agreement encompasses exclusive licensing, supply, and commercialization rights for Bofanglutide within India.
This collaboration underscores Lupin’s commitment to addressing the escalating prevalence of metabolic diseases in india. According to recent data, over 101 million adults in india are living with diabetes, and a notable portion of the population is either overweight or obese – approximately 146 million are overweight and about 50 million are obese. diabetes already affects roughly 90 million adults in the country.
Bofanglutide: A Dosing advantage
A key differentiator of Bofanglutide is its convenient fortnightly (every two weeks) dosing schedule. Rajeev Sibal, president, India region formulations, Lupin, highlighted this advantage, stating that it “reduces the number of injections by 50 per cent while delivering outcomes and clinically proven efficacy that matches or surpasses existing weekly formulations.” This reduced injection frequency aims to improve patient adherence, a critical factor in effective diabetes management.
Nilesh Gupta,managing director,Lupin,emphasized the broader significance of the partnership,stating,”We are offering the best solutions for managing chronic metabolic diseases like [diabetes],most urgent global health challenges. This partnership demonstrates our strategic focus on the GLP-1 class of drugs and highlights our dedication to delivering high-quality, innovative therapies for our patients.”
Gan & Lee’s Global Expansion Strategy
Gan & Lee executives indicated that the agreement with Lupin is part of a larger global expansion plan for their metabolic disease portfolio. The company recently secured an exclusive licensing deal in Latin America, signaling a proactive approach to extending the reach of bofanglutide and other metabolic therapies internationally.
Understanding GLP-1 Receptor Agonists
Glucagon-like peptide-1 (GLP-1) receptor agonists are a class of medications used to treat type 2 diabetes. They work by mimicking the effects of the naturally occurring GLP-1 hormone, which